Epileptic Encephalopathy Early Infantile CRISPR Cell Models

Early infantile epileptic encephalopathy (EIEE) is a group of severe epilepsy syndromes with onset in the first months of life. The incidence of EIEE is estimated at 1 in 10,000 to 1 in 20,000 live births (WHO, 2023). These disorders are characterized by refractory seizures, developmental delay, and often early mortality. The 5-year survival rate for severe EIEE subtypes is approximately 60-70% (NCI, 2022). Key risk factors include de novo mutations in genes encoding ion channels, synaptic proteins, and metabolic enzymes. The clinical impact is profound, with most patients requiring lifelong care and experiencing significant cognitive and motor impairments.

EIEE is an ideal model for mechanistic studies due to its monogenic origins in many cases, well-defined electrophysiological phenotypes, and the availability of patient-derived cell lines. Public datasets from the NCBI Gene database and ClinVar provide extensive mutation data. Open questions include the precise mechanisms by which specific mutations lead to network hyperexcitability, the role of genetic modifiers, and the development of targeted therapies. Gene-edited cell models are essential for dissecting these mechanisms and for preclinical drug screening.

The pathogenesis of EIEE involves disruption of key neuronal signaling pathways:

1. Ion Channel Dysfunction:

• • Mutations in voltage-gated sodium channels (SCN1A, SCN2A, SCN8A) alter action potential generation and propagation.
• • Potassium channel mutations (KCNQ2, KCNQ3) impair neuronal repolarization and increase excitability.
• • Calcium channel mutations (CACNA1A) disrupt neurotransmitter release.

2. Synaptic Vesicle Trafficking:

• • STXBP1 mutations impair SNARE complex assembly, reducing neurotransmitter release.
• • Mutations in SYNGAP1 disrupt synaptic plasticity and AMPA receptor trafficking.

3. Metabolic and Mitochondrial Pathways:

• • CDKL5 mutations affect mitochondrial function and neuronal maturation.
• • Mutations in genes like SLC2A1 (GLUT1 deficiency) impair energy supply to the brain.

Key deregulated networks in EIEE include:

• • Neuronal Excitability Network:
• • Sodium channels (SCN1A, SCN2A, SCN8A)
• • Potassium channels (KCNQ2, KCNQ3)
• • Calcium channels (CACNA1A)
• • Synaptic Transmission Network:
• • STXBP1, SYNGAP1, DLG4
• • AMPA and NMDA receptor subunits (GRIN1, GRIN2A)
• • Metabolic and Mitochondrial Network:
• • CDKL5, SLC2A1, POLG
• • Mitochondrial complex I and IV subunits
• • mTOR Signaling Pathway:
• • TSC1, TSC2, DEPDC5
• • mTORC1 activation leading to abnormal neuronal growth and excitability

Organoids offer advantages over 2D cultures by recapitulating 3D neuronal networks, allowing study of network-level excitability and drug responses.

• • SCN1A knockout mice: Recapitulate severe myoclonic epilepsy of infancy (Dravet syndrome).
• • KCNQ2 knockout mice: Show neonatal seizures and developmental delay.
• • STXBP1 heterozygous mice: Exhibit cognitive deficits and seizure susceptibility.
• • CDKL5 knockout mice: Display motor and cognitive impairments.
• • Zebrafish models: Used for high-throughput drug screening due to optical transparency and genetic tractability.

CRISPR-Cas9 gene editing enables the generation of isogenic cell lines with precise mutations found in EIEE patients. For example:

• • SCN1A knockout SH-SY5Y cells: Model loss of sodium channel function in inhibitory neurons.
• • KCNQ2 G279S knock-in HEK293T cells: Model a common missense mutation that reduces M-current.
• • STXBP1 R292H knock-in iPSC-derived neurons: Model synaptic vesicle fusion defects.
• • CDKL5 knockout iPSC-derived neurons: Model mitochondrial dysfunction and altered neuronal maturation.

These commercially available, sequence-verified models accelerate research by providing reproducible, isogenic backgrounds for functional studies and drug screening. They eliminate the confounding effects of genetic background variability seen in patient-derived lines.

Knockout and knock-in lines are used to validate the pathogenicity of specific genetic variants. For example:

• • SCN1A knockout in iPSC-derived neurons confirmed loss of sodium current and increased network excitability.
• • KCNQ2 G279S knock-in in HEK293T cells demonstrated reduced M-current and prolonged action potentials.
• • STXBP1 knockout in mouse neurons showed impaired synaptic vesicle fusion and reduced neurotransmitter release.

These models allow researchers to establish causal relationships between genotype and phenotype.

Isogenic pairs (wild-type vs. mutant) are used for high-throughput drug screening. For example:

• • SCN1A mutant cells are used to screen for compounds that enhance inhibitory interneuron function.
• • KCNQ2 mutant cells are used to identify potassium channel openers that restore M-current.
• • STXBP1 mutant cells are used to screen for compounds that enhance synaptic vesicle release.

Resistance modeling: Long-term exposure to antiepileptic drugs in mutant cells can reveal mechanisms of drug resistance and identify alternative therapeutic targets.

CRISPR synthetic lethality screens in EIEE mutant cells can identify genes that, when knocked out, selectively kill mutant cells while sparing wild-type cells. For example:

• • In SCN1A mutant neurons, screening for genes that are essential for survival in the context of reduced sodium current.
• • In KCNQ2 mutant cells, identifying genes that compensate for reduced M-current and are required for cell viability.

These screens can reveal novel therapeutic targets and biomarkers for patient stratification.